Q3 EPS Estimate for LENZ Therapeutics Increased by Analyst

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Stock analysts at HC Wainwright increased their Q3 2026 earnings per share estimates for shares of LENZ Therapeutics in a report released on Wednesday, August 12th. HC Wainwright analyst M. Caufield now anticipates that the company will earn ($1.02) per share for the quarter, up from their previous forecast of ($1.15). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for LENZ Therapeutics’ current full-year earnings is ($4.63) per share. HC Wainwright also issued estimates for LENZ Therapeutics’ Q4 2026 earnings at ($1.00) EPS, FY2026 earnings at ($4.35) EPS, FY2027 earnings at ($4.14) EPS, FY2028 earnings at ($2.27) EPS, FY2029 earnings at ($0.85) EPS and FY2030 earnings at $0.63 EPS.

LENZ Therapeutics (NASDAQ:LENZ) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($1.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.05) by $0.03. LENZ Therapeutics had a negative return on equity of 52.16% and a negative net margin of 586.74%.The business had revenue of $5.49 million during the quarter, compared to analyst estimates of $2.38 million.

Other analysts also recently issued reports about the stock. Weiss Ratings downgraded shares of LENZ Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday. Citigroup reiterated a “buy” rating on shares of LENZ Therapeutics in a report on Wednesday. Piper Sandler reduced their target price on shares of LENZ Therapeutics from $12.00 to $7.00 and set a “neutral” rating for the company in a research note on Wednesday. Finally, Zacks Research cut shares of LENZ Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 15th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $28.80.

LENZ Therapeutics Stock Performance

Shares of LENZ opened at $4.60 on Friday. The firm has a market cap of $144.53 million, a PE ratio of -1.12 and a beta of 0.65. The firm’s 50 day moving average price is $5.69 and its 200 day moving average price is $9.04. LENZ Therapeutics has a twelve month low of $4.53 and a twelve month high of $50.40.

Institutional Investors Weigh In On LENZ Therapeutics

Large investors have recently bought and sold shares of the business. BlackRock Inc. bought a new stake in shares of LENZ Therapeutics during the second quarter worth $13,019,000. UBS Group AG grew its stake in shares of LENZ Therapeutics by 30.8% during the fourth quarter. UBS Group AG now owns 1,571,738 shares of the company’s stock valued at $25,148,000 after purchasing an additional 370,122 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its holdings in shares of LENZ Therapeutics by 108.8% in the second quarter. Adage Capital Partners GP L.L.C. now owns 1,122,738 shares of the company’s stock valued at $32,907,000 after purchasing an additional 585,000 shares in the last quarter. Franklin Resources Inc. lifted its stake in shares of LENZ Therapeutics by 86.7% during the fourth quarter. Franklin Resources Inc. now owns 1,096,334 shares of the company’s stock valued at $17,541,000 after acquiring an additional 509,250 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of LENZ Therapeutics by 307.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,023,542 shares of the company’s stock valued at $16,378,000 after purchasing an additional 772,411 shares during the last quarter. 54.32% of the stock is currently owned by institutional investors.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.